Why the study?
Which immunochemical method is most reliable for determining digoxin levels in pregnant women, fetuses, and neonates?
Which immunochemical method is most reliable for determining digoxin levels in pregnant women, fetuses, and neonates?
Ultrafiltration of blood samples is necessary before immunochemical analysis to reliably monitor digoxin therapy in pregnant women and fetuses due to the presence of digoxin-like immunoreactive factors.
Answers are grounded in this paper and cite their sources.
Caution advised interpreting digoxin levels in pregnancy without ultrafiltration; leaves open optimal assay selection and outcome impact.
Four immunochemical methods for digoxin assay were used to analyse control samples, 33 amniotic fluid samples, 57 samples from digitalis-treated, non-pregnant women, 90 pregnancy serum samples, and 72 samples of fetal or neonatal serum with or without digoxin therapy. One hundred and five samples were also submitted to ultrafiltration before analysis. Three methods (RIA, TDX, AMERLITE) showed practically the same precision, while the precision of the DELFIA was markedly inferior. In the analysis of serum samples from digoxin-treated, non-pregnant women, RIA and TDX gave practically the same values, whereas AMERLITE and DELFIA gave significantly higher values. Pregnancy serum and fetal serum contain "digoxin-like immunoreactive factors", and the qualitative and quantitative effects of these interfering factors are different for each of the four methods. The greatest sensitivity to "digoxin-like immunoreactive factors" is shown by TDX and DELFIA, while the lowest interference by "digoxin-like immunoreactive factors" is found in the analysis of ultrafiltered samples, using the TDX method. The composition of the "digoxin-like immunoreactive factors" in pregnancy serum and in fetal serum is altered by digoxin therapy, and these changes have different effects on the various analytical methods. The concentration of "digoxin-like immunoreactive factors" in the serum of fetuses receiving digoxin is markedly lower than that of healthy fetuses. For the reliable monitoring of digoxin therapy in the maternal and fetal circulation, the blood samples must be submitted to ultrafiltration before analysis.
No takes yet. Share an insight, caveat, or question.
Schlebusch et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: